This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| International Genetics of Ankylosing Spondylitis Consortium | |
|---|---|
| Name | International Genetics of Ankylosing Spondylitis Consortium |
| Abbreviation | IGAS |
| Formation | 2007 |
| Type | Research consortium |
| Headquarters | multicenter |
| Region served | International |
International Genetics of Ankylosing Spondylitis Consortium The International Genetics of Ankylosing Spondylitis Consortium is a multinational research collaboration focused on the genetic architecture of ankylosing spondylitis, spondyloarthritis, and related autoimmune conditions. It brings together investigators from academic institutions, hospitals, and genomic centers to perform large-scale genome-wide association studies and functional follow-up, integrating clinical cohorts with biobank and sequencing resources.
The consortium originated from early genome-wide efforts that followed pioneering work at institutions such as Harvard University, University of Oxford, University of Cambridge, and Karolinska Institute, and drew on datasets from cohorts linked to University College London, Stanford University, and Massachusetts General Hospital. Founding meetings involved investigators affiliated with European Bioinformatics Institute, Wellcome Trust Sanger Institute, and National Institutes of Health, while early genomic platforms were provided by collaborations with Illumina, Affymetrix, and Broad Institute. Subsequent expansion included partnerships with groups at University of Queensland, University of Tokyo, Peking University, and University of São Paulo, reflecting engagement across Europe, North America, Asia, and South America.
Membership spans principal investigators, bioinformaticians, genetic epidemiologists, and clinicians from institutions such as Johns Hopkins University, University of California, San Francisco, University of Toronto, Monash University, University of Melbourne, Imperial College London, McGill University, ETH Zurich, University of Barcelona, Seoul National University, Oslo University Hospital, Addenbrooke's Hospital, Karolinska University Hospital, Guy's and St Thomas' NHS Foundation Trust, and University of Edinburgh. Governance models reference frameworks used by Human Genome Project consortia and the International HapMap Project, with data access policies shaped by precedents from UK Biobank, All of Us Research Program, and the 1000 Genomes Project. Funding and oversight have involved agencies such as Wellcome Trust, European Research Council, National Health Service, National Science Foundation, Medical Research Council (United Kingdom), and National Institute for Health and Care Research.
The consortium's objectives include identifying common and rare loci influencing ankylosing spondylitis susceptibility and progression, characterizing gene-environment interactions, and translating genetic discoveries into biomarkers and therapeutic targets. Research priorities build on discoveries at loci such as HLA-B, while leveraging analytic approaches used in studies of rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, and type 1 diabetes. The consortium situates its aims within translational pipelines exemplified by collaborations with pharmaceutical partners like GlaxoSmithKline, Novartis, Pfizer, Roche, and AstraZeneca and clinical guideline developers such as American College of Rheumatology and European League Against Rheumatism.
Major genome-wide association studies coordinated by the consortium replicated the central role of the HLA-B27 allele and uncovered non-HLA loci implicating genes and pathways connected to antigen presentation, the interleukin axis, and bone remodeling. Key implicated genes and regions identified in consortium analyses include ERAP1, IL23R, TYK2, RUNX3, CARD9, PTGER4, TNFSF15, ANKH, TRAF3IP2, FUT2, IL12B, SOCS1, JAK2, STAT3, NFKB1, ZC3H7B, BACH2, GPR35, CCL20, SLC22A5, PTPN22, and MUC5B. Findings have parallels with genetic architectures documented in large consortia such as GIANT (consortium), ENIGMA Consortium, Psychiatric Genomics Consortium, and International IBD Genetics Consortium. Functional studies informed by the consortium used approaches developed at Cold Spring Harbor Laboratory, Friedrich Miescher Institute for Biomedical Research, and Max Planck Institute for Molecular Genetics.
Analytic pipelines used by the consortium integrate genotype imputation referencing panels from the 1000 Genomes Project, Haplotype Reference Consortium, and UK10K, sequence data from Exome Aggregation Consortium, and annotation tools from Ensembl, GENCODE, and dbSNP. Methods include genome-wide association meta-analysis using software from PLINK (software), METAL (software), and GCTA (software), fine-mapping strategies informed by CAVIAR and FINEMAP, and expression quantitative trait locus mapping drawing on data from GTEx, ENCODE Project, and Roadmap Epigenomics Project. Biobank and cohort resources contributing data include UK Biobank, Biobank Japan, deCODE genetics, FinnGen, Estonian Biobank, Million Veteran Program, China Kadoorie Biobank, and regional registries linked to National Health Insurance (Taiwan) data systems.
The consortium collaborates with clinical trial networks and academic groups including INSIGHT (HIV consortium), International Network for Strategic Initiatives in Global HIV Trials, and rheumatology societies such as American College of Rheumatology and Asia Pacific League of Associations for Rheumatology, while partnering with translational centers like Translational Genomics Research Institute and Vector Institute. Industry partnerships include alliances with Illumina, Thermo Fisher Scientific, Genentech, and Bristol Myers Squibb for genotyping, sequencing, and functional validation. Data sharing and ethical governance draw on models from Global Alliance for Genomics and Health, ELIXIR, and BD2K initiatives.
Consortium findings informed genetic risk profiling efforts and contributed evidence cited in guidelines produced by American College of Rheumatology, European League Against Rheumatism, and national health bodies such as National Institute for Health and Care Excellence, influencing diagnostic pathways and stratified medicine strategies. Genetic insights have supported therapeutic development programs at AbbVie, Johnson & Johnson, and Merck & Co., and underpinned biomarker strategies evaluated in registries maintained by British Society for Rheumatology and National Data Guardian (United Kingdom). The consortium's work also shaped ethical and data governance discussions at forums convened by World Health Organization, Organisation for Economic Co-operation and Development, and Council of Europe.
Category:Genetics consortia